Calcium antagonists in secondary prevention after acute myocardial infarction: the Secondary Prevention Reinfarction Nifedipine Trial (SPRINT).

SPRINT was a double-blind, randomized placebo controlled multi-centre trial based in Israel, designed to test whether nifedipine 10 mg X 3 daily would reduce morbidity and mortality during 1 year follow-up in 2279 male and female survivors of acute myocardial infarction. 335 patients were adjudged to be trial deviations. 130 (5.7%) of patients died and 105 (4.6%) experienced a non-fatal myocardial reinfarction. Analysis of the results by trial medication is awaited.